Therapy reports

464 respiratory partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication and target analysis | Contract intelligence

527 musculoskeletal partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication analysis | Contract intelligence

506 dermatology partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication analysis | Contract intelligence

384 ophthalmics partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication and target analysis | Contract intelligence

842 hospital care partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication and target analysis | Contract intelligence

1,066 autoimmune partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic target analysis | Contract intelligence | Comprehensive deal directory

155 gynecology partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication and target analysis | Contract intelligence

The Leading Partnering Intelligence Platform for Life Science Dealmakers

Custom Executive Partnering Briefings apply Current Partnering’s proprietary pharma and biotech deal intelligence to your company, pipeline or strategic priorities. Each briefing delivers focused analysis of relevant deals, potential partners, financial benchmarks and market trends. Standalone briefings start from USD$3,995 with a free proposed table of contents and scope available on request.

Cancer Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026